

Special Issue

Role of Inflammasome Activation in Atherosclerosis

Message from the Guest Editors

Cardiovascular diseases (CVD) are still the predominant cause of death and morbidity, with atherosclerosis as the main underlying cause. Innate-immunity-induced inflammation plays a major role in promoting the atherosclerotic plaque, resulting in myocardial infarction and stroke. Inflammasome biology is one of the most exciting and rapidly growing areas in immunology. Inflammasome includes NLRP1, NLRP2, NLRP3, AIM2, and NLRC4 have attracted more attention in recent studies. We are pleased to invite you to help clarify the mechanism of inflammasome in atherosclerosis process, which will facilitate the development of precise therapeutic strategies for CVD. Since inflammasome activation has been shown to be an important mechanism driving atherogenesis, inflammation, and foam cell formation, it could emerge also as a crucial mechanism triggering vascular endothelial cell damage, vascular smooth muscle cells phenotypic switch, and subsequently, plaque destabilization. Until now, this hypothesis has not been investigated, and it could open a door to the revelation of a new mechanism in vascular pathology.

Guest Editors

Prof. Dr. Giampiero Girolomoni

Division of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, I-37126 Verona, Italy

Minghao Luo

Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/136987

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).